Advertisement

Post-Transplant Skin Cancer: The Influence of Organ and Pre-Transplant Disease

Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 146)

Post-transplant skin malignancies have been extensively studied [1–6], but the role of the transplanted organ in the occurrence of tumours is still discussed. This chapter reviews the epidemiological, clinical, and therapeutic aspects of skin cancers in populations of kidney (KTR), heart (HTR), and liver transplant recipients (LTR). Furthermore, some data on the impact of the pre-existing disease leading to organ failure are now available [7–10], and we consider here whether certain disorders warrant more intensive dermatological surveillance.

Keywords

Transplant Recipient Skin Cancer Basal Cell Carcinoma Primary Sclerosing Cholangitis Renal Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681–1691.PubMedCrossRefGoogle Scholar
  2. 2.
    Bouwes-Bavinck JN, Hardie D, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996; 61:715–721.PubMedCrossRefGoogle Scholar
  3. 3.
    Naldi L, Fortina AB, Lovati S, et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation 2000; 70:1479.PubMedCrossRefGoogle Scholar
  4. 4.
    Harden PN, Fryer AA, Reece S, et al. Annual incidence and predicted risk of nonmelanoma skin cancer in renal transplant recipients. Transplant Proc 2001; 33:1302–1304.PubMedCrossRefGoogle Scholar
  5. 5.
    Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49:397–406.PubMedCrossRefGoogle Scholar
  6. 6.
    Ulrich C, Schmook T, Sachse M, et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004; 30:622–627.PubMedCrossRefGoogle Scholar
  7. 7.
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4:905–913.PubMedCrossRefGoogle Scholar
  8. 8.
    Otley C, Cherikh WS, Salsche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol 2005; 53:783–790.PubMedCrossRefGoogle Scholar
  9. 9.
    Kauffman HM, Cherikh WS, Cheng U, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883–889.PubMedCrossRefGoogle Scholar
  10. 10.
    Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004; 66:383–389.PubMedCrossRefGoogle Scholar
  11. 11.
    Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77:574–579.PubMedCrossRefGoogle Scholar
  12. 12.
    Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Non melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147:950–956.PubMedCrossRefGoogle Scholar
  13. 13.
    Fortina AB, Caforio AL, Piaserico S, et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000; 19:249–255.PubMedCrossRefGoogle Scholar
  14. 14.
    Fuente MJ, Sabat M, Roca J, et al. A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients. Br J Dermatol 2003; 149; 1221–1226.PubMedCrossRefGoogle Scholar
  15. 15.
    Espana A, Redondo P, Fernandez A, et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995; 32:458–465.PubMedCrossRefGoogle Scholar
  16. 16.
    Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999; 40:27–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Lampros TD, Cobanoglu A, Parker F, et al. Squamous and basal cell carcinoma in heart transplant recipients. J Heart Lung Transplant 1998; 17:586–591.PubMedGoogle Scholar
  18. 18.
    Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102:222–227.Google Scholar
  19. 19.
    Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33:222–229.PubMedCrossRefGoogle Scholar
  20. 20.
    Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81:1093–1100.PubMedCrossRefGoogle Scholar
  21. 21.
    Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40:177–186.PubMedCrossRefGoogle Scholar
  22. 22.
    Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol 2006; 44:27–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transplant 2002; 8:939–944.CrossRefGoogle Scholar
  24. 24.
    Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transplant 2005; 11:1100–1106.CrossRefGoogle Scholar
  25. 25.
    Jimenez-Romero C, Manrique Municio A, Marques Medina E, et al. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and non-alcoholic liver diseases. Transplant Proc 2006; 38:2505–2507.PubMedCrossRefGoogle Scholar
  26. 26.
    Saigal S, Norris S, Muiesan P, et al. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transplant 2002; 8:482–487.CrossRefGoogle Scholar
  27. 27.
    Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or CsA-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80:1141–1150.PubMedCrossRefGoogle Scholar
  28. 28.
    Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34:84–91.PubMedCrossRefGoogle Scholar
  29. 29.
    Farge D. Kaposi’s sarcoma in organ transplant recipients. Eur J Med 1993; 2:339–343.PubMedGoogle Scholar
  30. 30.
    Serraino D, Angeletti C, Carrieri MP, et al. Kaposi’s sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation 2005; 80:1699–1704.PubMedCrossRefGoogle Scholar
  31. 31.
    Garcia-Astudillo LA, Levya-Cobian F. Human herpesvirus-8 infection and Kaposi’s sarcoma after liver and kidney transplantation in different geographical areas of Spain. Transplant Immunol 2006; 17:65–69.CrossRefGoogle Scholar
  32. 32.
    Becuwe C, Euvrard S, Bosshard S, et al. Kaposi’s sarcoma and organ transplantation: 22 cases. Ann Dermatol Venereol 2005; 132:839–843.PubMedCrossRefGoogle Scholar
  33. 33.
    Francès C, Lebbé C. Maladie de Kaposi du transplanté d’organe: faut-il prévenir, stabiliser ou guérir? Ann Dermatol Vénéréol 2005; 132:829–831.PubMedCrossRefGoogle Scholar
  34. 34.
    Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354:93–99.PubMedCrossRefGoogle Scholar
  35. 35.
    Gruber SA, Gillingham K, Sothern RB, et al. De novo cancer in cyclosporine-treated and non cyclosporine-treated adult renal allograft recipients. Clin Transplant 1994; 8:388–395.PubMedGoogle Scholar
  36. 36.
    Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999; 68:1859–1864.PubMedCrossRefGoogle Scholar
  37. 37.
    Chapman JR, O’Connell PJ, Bovington KJ, Allen RD. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. Transplantation 1996; 61:1699–1704.PubMedCrossRefGoogle Scholar
  38. 38.
    Van Duijnhoven E, Christiaans M, Schafer A, et al. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998; 30:1266–1267.PubMedCrossRefGoogle Scholar
  39. 39.
    Zanker B, Sohr B, Eder M, et al. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. Transplant Proc 1999; 31:1167.PubMedCrossRefGoogle Scholar
  40. 40.
    Errasti P, Manrique J, Lavilla J, et al. Autosomal-dominant polycystic kidney disease: high prevalence of graft loss for death-related malignancies and cardiovascular risk factors. Transplant Proc 2003; 35:1717–1719.PubMedCrossRefGoogle Scholar
  41. 41.
    Fitzpatrick PM, Torres VE, Charboneau JW, et al. Long-term outcome of renal transplantation in autosomal dominant polycystic kidney disease. Am J Kidney 1990; 15:535–543.Google Scholar
  42. 42.
    Johnston O, O’Kelly P, Donohue J, et al. Favorable graft survival in renal transplant recipients with polycystic kidney disease. Renal Fail 2005; 27:309–314.CrossRefGoogle Scholar
  43. 43.
    Xiol X, Guardiola J, Menendez S, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transplant 2001; 7:971–975.CrossRefGoogle Scholar
  44. 44.
    Benlloch S, Berenguer M, Prieto M, et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004; 4:596–604.PubMedCrossRefGoogle Scholar
  45. 45.
    Maffei F, Forti GC, Castelli E, Stefanini GF, Mattioli S, Hrelia P. Biomarkers to assess the genetic damage induced by alcohol abuse in human lymphocytes. Mutat Res 2002; 514:49–58.PubMedGoogle Scholar
  46. 46.
    Lindelhöf B, Dal H, Wolk K, Malmborg N. Cutaneous squamous cell carcinoma in organ transplant recipients. A study of the Swedish Cohort with regard to tumor site. Arch Dermatol 2005; 141:447–451.CrossRefGoogle Scholar
  47. 47.
    Salard D, Parriaux N, Derancourt C, et al. Manifestations dermatologiques chez les transplantés hépatiques. Ann Dermatol Venereol 2002; 129:1134–1138.PubMedGoogle Scholar
  48. 48.
    Perera GK, Child FJ, Heaton N, et al. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol 2006; 154:868–872.PubMedCrossRefGoogle Scholar
  49. 49.
    Romero-Vargas ME, Flores-Cortes M, Valera Z, et al. Cancers of new appearance in liver transplant recipients: incidence and evolution. Transplant Proc 2006; 38:2508–2510.PubMedCrossRefGoogle Scholar
  50. 50.
    Aseni P, Vertemati M, De Carlis L, et al. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation. Pathol Int 2006; 56:712–715.PubMedCrossRefGoogle Scholar
  51. 51.
    Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Transplant Proc 1998; 30:1124–1126.PubMedCrossRefGoogle Scholar
  52. 52.
    Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation. Cancer 1999; 85:1759–1764.CrossRefGoogle Scholar
  53. 53.
    Colina F, Lopez-Rios F, Lumbreras C, et al. Kaposi’s sarcoma developing in a liver graft. Transplantation 1996; 61:1779–1781.PubMedCrossRefGoogle Scholar
  54. 54.
    Aseni P, Vertemati M, Minola E, et al. Kaposi’s sarcoma in liver transplant recipients: morphological and clinical description. Liver Transplant 2001; 7:816–823.CrossRefGoogle Scholar
  55. 55.
    Marcellin AG, Roque-Afonso AM, Hurtova M, et al. Fatal disseminated Kaposi’s sarcoma following human herpesvirus 8 primary infections in liver transplant recipients. Liver Transplant 2004; 10:295–300.CrossRefGoogle Scholar
  56. 56.
    Woodle ES, Hanaway M, Buell J, et al. Kaposi’s sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Registry. Transplant Proc 2001; 33:3360–3361.Google Scholar
  57. 57.
    Otley CC, Maragh SL. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 2005; 31:163–168.PubMedCrossRefGoogle Scholar
  58. 58.
    Tessmer CS, Magalhaes LV, Keitel E, et al. Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 2006; 82:1792–1793.PubMedCrossRefGoogle Scholar
  59. 59.
    Fernandez A, Marcen R, Pascual J, et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006; 38:2453–2455.PubMedCrossRefGoogle Scholar
  60. 60.
    Ismail F, Mitchell L, Casabonne D, et al. Specialist dermatology clinics for organ transplant recipients significantly improve photoprotection and levels of skin cancer awareness. Br J Dermatol 2006; 155:916–925.PubMedCrossRefGoogle Scholar
  61. 61.
    Clowers-Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: randomized intervention of intensive vs. standard education. Arch Dermatol 2006; 142:712–718.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of DermatologyHôpital Edouard Herriot69437 LyonFrance

Personalised recommendations

Cite chapter

Buy options